Henry Ford Hospital researchers have identified two molecules that hold promise as a biomarker for measuring cartilage damage associated with osteoarthritis.
Researchers say the concentration of two molecules known as non-coding RNAs in blood, were associated with mild cartilage damage in 30 patients who were one year removed from reconstruction surgery to repair an anterior cruciate ligament (ACL injury).
The findings are described as significant in the ongoing search of biomarkers for osteoarthritis. “For various pathology reasons associated with the variability of the disease and challenging blood biochemistry, developing a biomarker for osteoarthritis has been very elusive. The next step is to expand the number of patients studied and determine whether the degree in blood concentration can determine if the cartilage damage will worsen over time,” says Gary Gibson, PhD, director of Henry Ford’s Bone and Joint Center. “Our ultimate goal is to develop a biomarker that can be used in the development of future treatments to prevent the progression of the disease.”
Release Date: Feb. 4, 2012
Source: Henry Ford Hospital